5 Intriguing Things Illumina's Management Said in Its Q3 Update
"Let the good times roll" might be a good theme for Illumina (NASDAQ: ILMN) in 2017. The gene-sequencing pioneer reported its third-quarter results on Tuesday. Illumina once again beat expectations, posting strong revenue and earnings growth, as well as bumping up its full-year 2017 guidance.
The company's management team fielded questions from analysts in a conference call following the earnings announcement. Here are five intriguing things Illumina's executives said in the third-quarter update that investors will want to know. (Quotes courtesy of S&P Global Market Intelligence.)
Image source: Getty Images.
Source: Fool.com
Novartis AG ADR Aktie
104,50 €
0,00 %
Leichtes Kaufinteresse bei Novartis AG ADR, mit mehr Buy- als Sell-Einschätzungen.
Ein leicht positives Kursziel von 112 € für Novartis AG ADR gegenüber dem aktuellen Kurs von 104.5 € wird gesehen.
